R
ecurrences of carcinoma of the uterine cervix develop in almost half of the patients treated for primary invasive cervical carcinoma. The majority of these recurrences occur in the pelvis without distant metastases. In this situation, radiotherapeutic or astolic pressure ú 100 or systolic pressure ú 180 mm Hg). Patients were also excluded in cases of an unconsurgical treatment is seldom an option, because most patients have already received radiotherapy and very few trolled infection, or concomitant or previous second malignancy. Patients with extreme obesity and those are suitable for exenterative surgery. In this situation, systemic chemotherapy is a remaining treatment option.
with a pacemaker or metallic implants in the HT target area were excluded because of possible complications Standard chemotherapy, still represented by cisplatin as monotherapy, results in an overall response rate of 20-from HT. Patients in this study were treated between September 1992 and December 1995. Written in-30%. [1] [2] [3] In patients who have previously been treated with pelvic irradiation the response rate in the pelvis is lower formed consent was obtained from each patient after the treatment procedure was fully explained. The than in the extrapelvic sites, with an upper limit in almost all studies of only 15%. 1, [4] [5] [6] [7] [8] The median duration of restudy was approved by the local Medical Ethical Committee. sponse is short (4-6 months), with a median survival of only 7 months. 1, [3] [4] [5] [6] 8, 9 A possible way of improving the cytotoxicity of Hyperthermia Treatment
Locoregional HT was administered with a 70-megacisplatin is by combination with hyperthermia (HT). Cytotoxicity of cisplatin in vitro and in vivo is potentihertz, 4 antenna-phased array system. 22 Hyperthermia was given at weekly intervals in combination with cisated by heat and increases almost linear with increasing temperature. Thermal enhancement is maximal platin. Heating started with a preheating phase with the goal of elevating the tumor temperature to 41 ЊC when HT and cisplatin are given simultaneously. [10] [11] [12] [13] [14] [15] Furthermore, there is substantial evidence that cisor higher. The effective heating period started when the maximum temperature in the tumor reached platin resistance can be circumvented by giving HT concurrently.
11, 16 -18 The biologic rationale for using HT 41 ЊC and lasted 60 minutes. If after 30 minutes of heating the maximum temperature was still below and cisplatin is therefore strong and formed the basis of this clinical study. Recently, the authors showed 41 ЊC, this point was taken as the starting point of the effective heating period. The maximum temperature that weekly locoregional HT in combination with cisplatin, 50 mg/m 2 /week for a maximum of 12 cycles, in the tumor tissue was not allowed to rise above 45 ЊC or to above 43 ЊC in normal tissue. If a patient was feasible with an acceptable toxicity. 19 The definitive results and toxicity of this weekly combination developed third-degree burns, treatment was discontinued. treatment schedule in 23 patients with a recurrence of a cervical carcinoma in a previously irradiated area are described in this article.
Thermometry Thermometry was performed in all patients. Before each HT treatment thermometry catheters were
MATERIALS AND METHODS

Patient Selection
placed in the bladder, rectum, and vagina. When possible, a catheter was positioned in the tumor. The cathPatients were eligible if they had a cytologically or histologically confirmed recurrent cervical carcinoma, eters used were thin (1 mm) closed-end teflon catheters, Thermistor catheter, high flow 5-French, 40-cm for which neither surgery nor radiotherapy were considered to be a realistic treatment option. A lesion long (Angiomed 0015-0040; Angiomed Nederland, Eemnes, The Netherlands); they were removed after measurable in one or two dimensions, located within the area intended to be heated, was required. In addieach treatment. Just before the start of each treatment, multithermocouple probes (Ella CS; Hradec Králové, tion, an Eastern Cooperative Oncology Group performance status 20 of°2, an adequate bone marrow (leuCzech Republic) were inserted in the catheters. Temperature sensors were located at fixed intervals of 0.5 kocyte count ¢ 3.5 1 10 3 /mL and platelet count ú 100 1 10 3 /mL) and adequate renal function (glomerular or 1 cm and related to the position within the catheter, which was recorded by X-rays shortly before treatfiltration rate [ 23 and the specific temperature data were calculated with Hyperprevious 6 months were excluded as were patients with cardiac disease (myocardial infarction within the thermia Evaluation Software (HES -Academic Medical Center, Amsterdam, The Netherlands). In addition, previous 6 months, unstable angina pectoris, or congestive heart failure) or uncontrolled hypertension (di-E-field probes were positioned in the rectum and va-gina for heat steering purposes according to the meaputerized tomography (CT) scan of the abdomen and pelvis, chest X-ray, bone scan, electrocardiogram, sured E-fields.
audiogram, squamous cell carcinoma antigen (SCCThermal Parameters Ag), and a complete blood chemistry survey. All paAll measurements of temperature at all intratumoral tients were considered evaluable for response regardsites were utilized for analysis. For each HT treatment, less of the number of received cycles of HT and cistime-averaged temperatures achieved in at least 20%, platin. Response was evaluated every four cycles with 50%, and 90% of all measured tumor temperature CT scan and gynecologic examination. In case of propoints were determined and expressed as T20, T50, gressive disease after four cycles or no response after and T90, respectively, in ЊC. In addition, the T50 above eight cycles, therapy was stopped. The maximum 41 ЊC was calculated and expressed in minutes; this number of cycles given was 12. reflected the average duration of a tumor temperature Tumor response and duration of response were above 41 ЊC in at least 50% of the measured tumor defined according to the World Health Organization temperature points.
(WHO) criteria. 24 Complete response (CR) was defined as disappearance of all known disease for a minimum Cisplatin Treatment of 1 month. Partial response (PR) was defined as a Patients were treated with cisplatin 50 mg/m 2 intrave-50% or greater decrease in measurable disease in the nously (i.v.) once a week in combination with HT. Cistreatment field for a least 1 month. In addition, no platin was given in 250 mL NaCl 3% in 90 minutes, appearance of new lesions or progression of any exideally starting 30 minutes before the effective heating isting lesion was allowed. Progressive disease (PD) was period began. In practice, cisplatin infusion was defined as a 25% or greater increase in the size of started 10 minutes before the start of heating. Prehymeasurable disease in the treatment field or the apdration consisted of 1 L NaCl 0.9% over 4 hours and pearance of new lesions. The remaining patients had posthydration of 2 L NaCl 0.9% (with 40 mMol KCl stable disease (SD). In the case of measurable disease and 20 mMol MgSO 4 ) over 16 hours. If diuresis was with both CT scan and gynecologic examination, the õ600 mL per 6 hours, patients received 100 mL of best response of both was taken into account. mannitol 20%. If this was ineffective, 5 mg furosemide
Response duration was measured from the start was added. Platinum dose was adjusted to 50% in case of treatment in case of PR or, in the case of CR, from of GFR õ 60 mL/minute. Treatment was postponed the date the CR was first recorded. in case of GFR õ 45 mL/minute. If the leukocyte count Overall survival was measured from the start of was õ2 1 10 3 /mL and/or the platelet count was õ75 1 treatment. The duration of survival was calculated 10 3 /mL, treatment was postponed until recovery. When from this date until the date of analysis (December 1. treatment had to be postponed for longer than 3 weeks 1995). the patient was removed from the study.
SCC-Ag response was defined as follows: CR was defined as normalization (õ 1.9 ng/mL), PR as a deSupportive Treatment crease of ¢50% and PD as an increase of ¢25%. The Prophylactic antiemetic treatment was comprised of remaining patients had SD. SCC-Ag was measured in ondansetron 2 times a day, 8 mg orally, and was the serum with a Microparticulate Enzyme Immunostarted 1 hour before cisplatin treatment. In case oral assay (Abbott Laboratories, Abbott Park, IL). treatment was not possible, ondansetron was given All patients were considered evaluable for toxicity i.v. If treatment with ondansetron alone failed, dexa-(WHO grading system 24 ). Toxicity concerning hearing, methasone, 20 mg i.v., was added. In these patients, fatigue, hypomagnesemia, and weight loss was scored ondansetron and dexamethasone were given together according to the Common Toxicity Criteria of the Nain the next cycles, 1 hour before cisplatin. In October tional Cancer Institute of Canada (NCIC). Toxicity was 1993, after inclusion of seven patients, this policy was monitored weekly during treatment. Ototoxicity was changed to the combination of ondansetron and dexamonitored with audiometry at the end of treatment or methasone i.v. starting in the first cycle. In case of earlier when clinically indicated. failure in these patients, metoclopramide suppositoPatients were seen regularly at 1, 2, 3, 5, 7, 9, and ries, 3 1 20 mg, were added and dexamethasone orally 11 months after treatment and every 3 months there-(when needed) on the following schedule: Days 2 -3, after. 2 1 3 mg and Days 4 -5, 2 1 1.5 mg.
Evaluation of Treatment Statistical Analysis
Thermal parameters for responders and nonrespondPretreatment evaluation included a complete medical history, physical and gynecologic examination, comers were compared with the help of SPSS (SPSS Inc., / 7b4e$$0921 02-11-97 08:46:26 canxa W: Cancer Overall, 169 cycles of HT and cisplatin were given, with a median of 8 cycles (range, 1 -12 cycles) per patient. (1 time), and flu (1 time). 2 7 The number of cycles was given as planned in 14 cles. In 9 patients toxicity was the main reason therapy was stopped prematurely: GFR õ 45 mL/min (2 patients), subjective toxicity such as fatigue and malaise (5 patients), hearing loss (1 patient), and skin burn (1 Chicago, IL) statistical software using the two-tailed, patient). unpaired Student's t test. Correlation of clinical parameters (such as age, performance status, weight, and Thermometry and Thermal Parameters histology) with response was analyzed with the MannTumor thermometry could be performed in 21 of the Whitney nonparametric test and the chi-square test.
23 patients. It was not possible to measure temperaThe survival proportion was estimated using the ture in the tumor of two patients. The mean number Kaplan -Meier method.
of tumor probes was 1 (range, 1 -3 probes), with a median number of 9 measuring points (range, 2 -21 measuring points). The mean time needed to reach a
RESULTS
Patient and Tumor Characteristics
temperature ú 41 ЊC was 13 minutes (standard deviation [SD] 7.6). After reaching this temperature, treatThe characteristics of the 23 patients treated are presented in Table 1 . There were no additional patients ment was continued for a mean of 60 minutes (SD 4.1) The thermal parameters are presented in Table 2 , as who started therapy but did not complete it. The mean age was 45 years (range, 27 -71 years). The median the mean of the measured temperature in every patient. There were no differences in tumor thermometry interval between the first diagnosis of the primary tumor and recurrence was 15 months (range, 3 -189 data, when these were expressed either as the mean of all treatments (n Å 156) or as the mean of the meamonths). Five patients had distant metastases: bone metastases (two patients), with the major recurrence sured temperature in every patient (n Å 21). Mean oral temperature at the end of treatment was 37.6 ЊC (SD site in the central pelvis and pelvic sidewall or a parailiac lymph node, distant lymph node metastases (two 0.3), with an upper range to 38.2 ЊC. patients), with the major recurrence site both times in the central pelvis and pelvic sidewall, and a lymphan-
Hyperthermia-Related Toxicity
Subcutaneous fatty necrosis occurred in 9 patients gitis carcinomatosa on the skin (also located in the HT treatment area) (one patient) with the abdominal wall (10% of the cycles), with pain as its most important manifestation. However, none of these patients had as the major recurrence site. In all five patients the main tumor burden was located in the area intended to stop treatment. Two patients developed skin burns.
One sustained a first-degree burn on the vulva, which to be treated with HT and cisplatin. healed in 2 weeks, and the other sustained a thirdthe other patients GFR remained ú 45 mL/minute. The overall GFR decreased to 66% of the calculated degree burn on the buttock, which healed spontaneously in 2 months. No further treatment was given in GFR at the beginning of therapy, with a range of 33 -108%. During follow-up after therapy the GFR imthis last patient.
Mild pain during HT was observed in 18% of the proved to a value of 77% of the starting value. The mean calculated GFR at the beginning of therapy was cycles. This pain was power-related, with a short duration (seconds-minutes) and reacted well to adjust-91 mL/minute (SD 34). Tinnitus (Grade 2), developed in six patients. ments in heat steering. In none of these patients was the treatment stopped. Thermometry-catheter-related However, in only one patient did symptomatic hearing loss occur after four cycles, which led to treatment complications were scarce. In one patient the catheter dislocated into the abdominal wall and had to be rediscontinuation. In ten other patients asymptomatic high frequency hearing loss was recorded in the audiomoved surgically under local anesthesia.
grams. Mild peripheral neurotoxicity, mainly paresthesia, was observed in six patients and Grade 2 toxicToxicity ity in one patient. Significant weight loss occurred in All patients were evaluable for toxicity. Table 3 shows 14 patients, with a mean weight loss of 4.8% (range, the overall toxicity. Grade 3 toxicity (mainly nausea/ 0 -11%). Infectious complications occurring outside vomiting) occurred in 8 of 23 patients, but in only 12 periods of neutropenia were observed in five patients, of 169 cycles (7%). Two patients refused further therlower urinary tract infection in two patients, pyeloneapy. In the remaining patients with Grade 3 nausea/ phritis in two patients, and a superficial skin infection vomiting, toxicity could be reduced to Grade 2 or less with Staphylococcus aureus in one patient. No alopecia by changing the antiemetic policy as described earlier.
was observed. This resulted in Grade 1 nausea/vomiting in two patients and Grade 2 toxicity in four patients.
After the change in the standard antiemetic pro-
Response and Survival
All patients were evaluated for response, including the phylaxis as described earlier, Grade 3 toxicity occurred only in 7 of 131 cycles (5.3%). The two patients who two patients who received only one and two cycles, respectively. The median follow-up was 8 / months stopped therapy were both treated before the change in antiemetic prophylaxis. Reversible hematologic tox-(range, 2 -39 / months). Response was observed in 12 of 23 patients, resulting in a response rate of 52% (95% icity (Grade 3) was observed in four patients without concurrent febrile neutropenia or bleeding complicaconfidence interval [CI], 31 -73%); 2 pathologic CR (duration 20 / and 35 / months, respectively), 1 CR (dutions. In five patients severe hypomagnesemia was observed; clinical signs or symptoms of hypomagneseration 33 / months), and 9 PR with a median duration of 7 / months (range, 4 -26 / months). Salvage surgery mia were not encountered. The lowest mean value observed was a magnesium of 0.56 mMol/L (SD 0.19).
became possible in 3 of 12 responding patients (2 pathologic CR and 1 PR), whose tumors were preThirteen patients had mild (Grade 1) renal toxicity. Grade 2 renal toxicity (in one patient) completely reviously considered unresectable. In two patients no tumor cells were found in the resection specimen and solved after a treatment delay. In two patients therapy was stopped due to a decrease in renal function (GFR in the other patient, with a tumor decrease of 80%, a complete resection could be performed. The median õ 45 mL/minute) that did not resolve in 3 weeks. In (range, 2 -13 months), with 1 of 5 patients alive at last sponders.
Response Assessment Evaluation
duration of response in all patients was 9.5 / months Tumor response was assessed with the help of CT and/ (range, 4 -35 / months). Response was observed after or gynecologic examination. In four patients tumor a median number of 8 cycles (range, 2 -12 cycles). In evaluation was only possible by CT scan and in two 8 of 12 responders there was an additional decrease patients only by gynecologic examination. in tumor greatest dimension during further treatment.
In 17 of the 23 patients the results of response In 2 of 12 patients the tumor greatest dimension did assessment by either CT scan or gynecologic examinanot decrease any further and in 2 of 12 patients thertion could be compared. Gynecologic and CT scan apy was stopped at the moment of the observed reassessment were independently performed by a gynesponse.
cologist and radiologist, respectively. In 14 of 17 paThe overall median survival was 8
/ months (range, tients response assessment by both modalities was 2-39 / months). In the responding patients median identical, resulting in an observed agreement of 82% survival was 12
/ months (range, 6 / -39 / months) with (Kappa 0.62). In 2 of the 3 patients with a discongruent 10 of 12 patients still alive at last follow-up, and in observation, a nonconfirmed 50% regression by CT the nonresponding patients the median survival was scan was found with a clear confirmed regression at 6 months (range, 2 -12 months) with no patient still gynecologic examination. alive at last follow-up. The overall 1-year survival was 42% (standard error of the mean 11%).
In three of five patients with distant metastases,
Squamous Cell Carcinoma Antigen
Twenty patients had either a squamous cell carcinoma a difference in response was observed between the pelvic HT treatment area and the area of distant me-(n Å 18) or a mixed histology (n Å 2). In 11 of these 20 patients (55%), the SCC-Ag level (normal level õ tastasis. One patient had a PR in the HT treatment area with SD in the bone. Two other patients had SD 1.9 ng/mL) was increased before the start of therapy. The mean value was 41.8 ng/mL (range, 11 -123 ng/ in the HT treatment area, but showed clear progression in distant lymph nodes. In two of five patients mL). In 7 of 11 patients, SCC-Ag decreased ú 50%, resulting in a response rate of 64%. Only one of these with distant metastases there was no difference between both sites. In one patient there was SD in both patients did not have a clinical response. In 5 of 11 patients (45%) there was even a complete normalizathe HT treatment area and the bone. In the other patient with lymphangitis carcinomatosa of the skin both tion. The positive predictive value for detecting a clinical response in the case of a SCC-Ag response was 86% the deeply located tumor and the lymphangitis responded to therapy; however, the lymphangitis of the and the negative predictive value in the case of no SCC-Ag response was 100%. The sensitivity of a SCCskin was also located in the HT treatment area. Therefore, in 2 of the 5 patients with distant metastases, a
Ag response for detecting a clinical response was 100% and the specificity was 75%. Four of the six correctly PR was observed with a duration of 4 and 8 months, respectively. The median survival was 9
/ months identified SCC-Ag responders had developed clinical / 7b4e$$0921 02-11-97 08:46:26 canxa W: Cancer PD at last follow-up; in all four patients SCC-Ag inuse cisplatin and HT in a dose of 50 mg/m 2 /week for a period of 6 weeks. [26] [27] [28] [29] [30] Because the authors believed creased significantly. that 6 weekly cycles might not be sufficient for induction of worthwhile responses, they chose to treat pa- 1, 2, 6 This combination of weekly HT and cisplatin proved to be feasible in a response rate of 52% (95% CI, 31 -73%). No relation was found between treatment outcome and cliniwith acceptable toxicity.
DISCUSSION
19,31
The received dose intensity was 37.9 mg/m 2 /week, cal parameters such as age, weight, performance status, and histology. Salvage surgery became possible in which represented 88% of the projected dose intensity. The median total dose given was 350 mg/m 2 . Dose 3 of 12 responding patients (2 pathologic CR and 1 PR), whose tumors were previously considered unrereductions were necessary in 19% of the cycles and postponement of therapy was necessary in 6%. In 9 of sectable. In two patients no tumor cells were found in the resection specimen.
23 patients therapy was stopped prematurely because of subjective or objective toxicity. Overall toxicity was In patients with a pelvic recurrence after radiotherapy the response rate after treatment with cismoderate. The most common toxicity observed was Grade 3 nausea and vomiting in 8 of 23 patients, but platin alone is low, with an upper limit of only 15% in most studies. These responses are short, with an overonly in 7% of the cycles. The frequency and severity of nausea and vomiting was equal to that observed all median survival of only 7 months. 1,4 -6,8,9 In a study by Lele et al. 4 with weekly cisplatin in a dose of 1 mg/ in other weekly cisplatin-containing regimens without HT. 3, 25, 32, 33 Other observed Grade 3 toxicity (hematokg for 6 cycles, but without HT, the response rate in patients with previously irradiated pelvic recurrences logic and hypomagnesemia) did not result in complications or clinical sequela. was õ10%. In contrast, Daly et al. 3 claimed a 50% response rate (7 of 14) in patients with previously irraAt the end of therapy an overall GFR decrease to 66% of the initial value was observed. When cisplatin diated pelvic recurrences. They gave 4 weekly cycles of cisplatin, 50 mg/m 2 , followed in responders by 4 was given without HT for only 6 cycles at a dose of 50 mg/m 2 , a GFR decrease to 80% of the initial value more cycles every 2 weeks. However, in this study only 58% of the recurrences were histologically proven and was observed. 25 Other studies with weekly cisplatin at different dose levels also resulted in nephrotoxicity, in only 70% of the cases was response confirmed by CT scan or ultrasound. The overall median response but comparison with the current results is inappropriate because of differences in dose intensity, total dose, duration was 6 months, the median survival was 8 months, and the 1-year survival was 28%.
and renal function at the start of therapy. 4, 6, 32 Ototoxicity (mostly asymptomatic hearing loss) The observed median duration of response of 9.5 / months (range, 4 -35 / months), the median overall appeared to occur more frequently than previously described with cisplatin alone, 33, 34 although some of survival of 8 / months (range, 2 -39 months), and the 1-year survival of 42% with the combination of weekly these findings may be explained by the meticulous examination including standard audiometry. The oblocoregional HT and cisplatin appears promising in comparison to these historic data. The biologic ratioserved neurotoxicity was in line with other observations. 3, 33 Other relevant toxicity were a mean weight nale for the combination of HT and cisplatin is strong and the clinical results are compatible with the obloss of almost 5% and -infrequent -infectious problems. served magnitude of thermal enhancement of cytotoxicity in vitro and in vivo.
11,12,15 Another observation, HT-related toxicity, such as reversible pain and subcutaneous fatty necrosis, was observed, but did not which was also in line with the thermal enhancement of cisplatin cytotoxicity, was the observed difference result in treatment discontinuation. Skin burns occurred in two patients, but healed spontaneously. The in response in three of five patients with tumor in both the HT treatment area and in a distant metastatic site.
only thermometry-catheter-related complication was a catheter dislocation. A report by Planting et al. 25 showed that the maximal tolerable dose of cisplatin without HT, given once
The target temperature (T ú 41 ЊC) was not able to be reached in all tumor points. However, T20, T50, weekly for 6 cycles, was 85 mg/m 2 /week; 50 mg/m 2 / week did not cause serious toxicity. A few clinical studand T90 were adequate in comparison to other reports. 35, 36 Theoretically, these temperatures should be ies in different tumors showed that it was feasible to / 7b4e$$0921 02-11-97 08:46:26 canxa W: Cancer high enough to increase the cytotoxicity of cisplatin, alone will be initiated in the Netherlands in cooperation with several European institutions. Because the because this is a linear process starting at 37 ЊC.
10,11
Although in general temperatures, expressed as T20, most benefit (with a potential for salvage surgery) can be expected in patients with a local recurrence only T50, and T90, were higher in responding patients than in nonresponding patients, this difference was not stawithout distant metastases, the trial will be limited to those patients. tistically significant. This may be caused by the relatively low number of patients with the implication of limited statistical power, because Issels et al. 35 were
